Current treatment status-Undergoing active treatment-No response Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Looking for older patients with acute myeloid leukemia to test a new treatment combination

Posted by on Jun 14, 2019 in Leukemia | 0 comments

In a nutshell This study is evaluating how well CPI-613 plus chemotherapy works in older patients with acute myeloid leukemia (AML) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is taking place across the United...

Read More

Evaluating quality of life after pembrolizumab treatment for classical Hodgkin lymphoma

Posted by on Jun 5, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 2 study evaluated the impact of pembrolizumab (Keytruda) on the quality of life of patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. This study concluded that the overall quality of life and health status was improved for these patients. Some background Most patients...

Read More

Evaluating the FMT regimen before a stem cell transplant in patients with aggressive non-Hodgkin lymphoma

Posted by on May 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of the FMT (fludarabine, melphalan, total body irradiation) regimen in patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that this regimen was well-tolerated and effective. Some background Many patients with aggressive NHL...

Read More

Looking for participants with advanced colorectal cancer to test a new targeted treatment with DS-8201a

Posted by on May 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness and safety of DS-8201a in the treatment of advanced HER2 positive colorectal cancer. The main outcome to be measured is the tumor response to the treatment and side effects.  The details The standard treatment to advanced colorectal cancers is surgery, chemotherapy and radiation...

Read More

Evaluating polatuzumab vedotin and pinatuzumab vedotin for relapsed or refractory NHL

Posted by on May 20, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) combined with either polatuzumab vedotin (pola) or pinatuzumab vedotin (pina) for patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that pola was associated with better...

Read More

Searching for patients with colorectal cancer to test this new treatment combination

Posted by on May 19, 2019 in Colorectal cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for advanced or unresponsive colorectal cancer (CRC) and other solid tumors.  The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...

Read More

Searching for patients with triple negative breast cancer to test this new treatment combination

Posted by on May 19, 2019 in Breast cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for triple negative breast cancer (TNBC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...

Read More

Is combined treatment with erlotinib and bevacizumab effective in non-small cell lung cancer?

Posted by on May 18, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness of erlotinib (Tarceva) and bevacizumab (Avastin) compared ti erlotinib alone in non-small cell lung cancer (NSCLC). They found that combined treatment improved survival after 12 months. Some background Non-small cell lung cancer (NSCLC) is a common type of lung cancer (LC)....

Read More

Combination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma

Posted by on May 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients.  Some background Patients with NHL are often treated with targeted therapies....

Read More

Combination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma

Posted by on May 9, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).   This study concluded that this combination appears safe and effective for these patients.   Some background Patients...

Read More

Evaluating chemotherapy regimens before stem cell transplantation for patients with non-Hodgkin’s lymphoma

Posted by on Apr 25, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of BEAM chemotherapy versus BUCYVP16 chemotherapy in patients with non-Hodgkin’s lymphoma (NHL) before autologous stem cell transplantation (ASCT). This study concluded that these regimens were similarly safe and effective for these patients before ASCT. Some background For patients with NHL...

Read More

Inotuzumab ozogamicin for patients with relapsed/unresponsive acute lymphoblastic leukemia

Posted by on Apr 24, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of inotuzumab ozogamicin (Besponsa) for patients with relapsed or unresponsive acute lymphoblastic leukemia.   This study concluded that this treatment was safe and effective for these patients. Some background Inotuzumab ozogamicin (InO) is a targeted...

Read More